The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a study to measure the effect that various doses of LY2409021 have on blood sugar
levels and on the amount of glucose released by the liver, when glucagon is given to increase
these. Each participant may receive up to 2 single doses of LY2409021 in 2 different study
periods, with a minimum 13-day washout between dosing periods. This study is approximately 9
weeks long, not including screening. A screening appointment is required within 6 weeks prior
to the start of the study.